| Title |
Application of personalized medicine to chronic disease: a feasibility assessment
|
|---|---|
| Published in |
Clinical and Translational Medicine, December 2013
|
| DOI | 10.1186/2001-1326-2-16 |
| Pubmed ID | |
| Authors |
Ruslan Dorfman, Zayna Khayat, Tammy Sieminowski, Brian Golden, Renee Lyons |
| Abstract |
Personalized Medicine has the potential to improve health outcomes and reduce the cost of care; however its adoption has been slow in Canada. Bridgepoint Health is a complex continuous care provider striving to reduce the burden of polypharmacy in chronic patients. The main goal of the study was to explore the feasibility of utilizing personalized medicine in the treatment of chronic complex patients as a preliminary institutional health technology assessment. We analyzed stroke treatment optimization as a clinical indication that could serve as a "proof of concept" for the widespread implementation of pharmacogenetics. The objectives of the study were three-fold:1. Review current practice in medication administration for stroke treatment at Bridgepoint Health2. Critically analyze evidence that pharmacogenetic testing could (or could not) enhance drug selection and treatment efficacy for stroke patients;3. Assess the cost-benefit potential of a pharmacogenetic intervention for stroke.Review current practice in medication administration for stroke treatment at Bridgepoint HealthCritically analyze evidence that pharmacogenetic testing could (or could not) enhance drug selection and treatment efficacy for stroke patients;Assess the cost-benefit potential of a pharmacogenetic intervention for stroke.We conducted a review of stroke treatment practices at Bridgepoint Health, scanned the literature for drug-gene and drug-outcome interactions, and evaluated the potential consequences of pharmacogenetic testing using the ACCE model.There is a substantial body of evidence suggesting that pharmacogenetic stratification of stroke treatment can improve patient outcomes in the long-term, and provide substantial efficiencies for the healthcare system in the short-term. Specifically, pharmacogenetic stratification of antiplatelet and anticoagulant therapies for stroke patients may have a major impact on the risk of disease recurrence, and thus should be explored further for clinical application. Bridgepoint Health, and other healthcare institutions taking this path, should consider launching pilot projects to assess the practical impact of pharmacogenetics to optimize treatment for chronic continuous care. |
X Demographics
The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 21% |
| India | 5 | 21% |
| Canada | 4 | 17% |
| Switzerland | 2 | 8% |
| Australia | 1 | 4% |
| United Kingdom | 1 | 4% |
| Austria | 1 | 4% |
| Ukraine | 1 | 4% |
| Unknown | 4 | 17% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 67% |
| Practitioners (doctors, other healthcare professionals) | 4 | 17% |
| Scientists | 4 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| Spain | 1 | 3% |
| Unknown | 30 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 25% |
| Researcher | 6 | 19% |
| Student > Ph. D. Student | 5 | 16% |
| Student > Bachelor | 2 | 6% |
| Student > Postgraduate | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 6 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 41% |
| Agricultural and Biological Sciences | 3 | 9% |
| Social Sciences | 3 | 9% |
| Psychology | 2 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Other | 4 | 13% |
| Unknown | 5 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 February 2014.
All research outputs
#1,880,884
of 25,373,627 outputs
Outputs from Clinical and Translational Medicine
#72
of 1,060 outputs
Outputs of similar age
#20,772
of 320,275 outputs
Outputs of similar age from Clinical and Translational Medicine
#1
of 2 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,060 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,275 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them